Pharmacology & Therapeutics

Article	Citations
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	395
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	392
Editorial Board	286
Collateral lethality: A unique type of synthetic lethality in cancers	274
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	244
Adenosine receptor signalling as a driver of pulmonary fibrosis	226
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	210
Inflammation, lipids, and pain in vulvar disease	190
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	183
Potential neonatal toxicity of new psychoactive substances	182
The role of macrophages in asthma-related fibrosis and remodelling	166
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	155
Endothelial dysfunction as a complication of anti-cancer therapy	154
In cancer, all roads lead to NADPH	149
Matrikines in the skin: Origin, effects, and therapeutic potential	138
Unfolded protein responses: Dynamic machinery in wound healing	137
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target	122
Non-canonical G protein signaling	120
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	120
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	118
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	118
TAAR1 as an emerging target for the treatment of psychiatric disorders	117
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	116
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	114
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	107

Boron in cancer therapeutics: An overview	105
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	104
Contribution of non-selective membrane channels and receptors in epilepsy	101
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	95
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	92
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	89
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	88
Cell-based therapies for vascular regeneration: Past, present and future	87
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors	86
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	85
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	84
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	84
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	81
Dysregulation of metabolic pathways in pulmonary fibrosis	80
Pharmacological treatment of cardiogenic shock – A state of the art review	79
TLR4 biased small molecule modulators	79
Natural products that alleviate depression: The putative role of autophagy	78
Bispecific antibodies for the treatment of neuroblastoma	78
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	76
Editorial Board	75
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	74
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	74
Review: Sex-related differences in the treatment of cardiac arrhythmia	73
Wnt signaling: A prospective therapeutic target for chronic pain	71
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	70
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	69
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	69
PGRMC1: An enigmatic heme-binding protein	69
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	66
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	66
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	66
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	66
DNA methylation in cell plasticity and malignant transformation in liver diseases	65
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	65
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	64
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	64
Addiction and the kynurenine pathway: A new dancing couple?	63
Stabilizing the neural barrier – A novel approach in pain therapy	62
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	61
Signal transduction in primary cilia – analyzing and manipulating GPCR and second messenger signaling	61
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	60
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	60
Editorial Board	59
The role of drug-metabolizing enzymes in synthetic lethality of cancer	59
Advances in pathogenesis and therapeutic strategies for osteoporosis	59
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	59
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	59
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	58
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	57
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	56

Recent advances in riboflavin transporter RFVT and its genetic disease	56
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	56
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	55
Therapeutic targeting of DNA methylation alterations in cancer	55
The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies	55
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	54
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	53
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	53
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	52
Regulation of feeding and therapeutic application of bioactive peptides	52
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	51
Optimizing drug therapies in cardiac amyloidosis	51
MicroRNAs in drug addiction: Current status and future perspectives	49
Organic anion transporters in remote sensing and organ crosstalk	49
Editorial Board	49
Editorial Board	49
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	49
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	48
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	48
Pharmacological potential of cyclic nucleotide signaling in immunity	48
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	47
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	47
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	47
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	46
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	46
Emerging methods for and novel insights gained by absolute quantification of mitochondrial DNA copy number and its clinical applications	45
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	45
CDNF and ER stress: Pharmacology and therapeutic possibilities	45
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	45
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	44
Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo	44
A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer	44
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?	43
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	43
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	43
G protein-coupled estrogen receptor biased signaling in health and disease	43
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	43
Resolving inflammation by TAM receptor activation	43
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	43
Editorial Board	43
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	43
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	43
The role and participation of immune cells in the endometrial tumor microenvironment	43
Editorial Board	42
Modulation of hyaluronan signaling as a therapeutic target in human disease	42
Molecular mechanisms of ferroptosis and their involvement in brain diseases	42
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	42
Exploring the landscape of post-translational modification in drug discovery	42
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	41
Extracellular vesicles in cancer diagnostics and therapeutics	41
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	41
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	41
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	41
Understanding the molecular bridges between the drugs and immune cell	40
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	40
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	39
Potential targeting of the tumor microenvironment to improve cancer virotherapy	39
Platelet lipid metabolism in vascular thrombo-inflammation	39
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	39
Editorial Board	38
Early life adversities, psychopathologies and novel pharmacological strategies	38
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	38
Editorial Board	38
From bench to clinic: Emerging therapies for corneal scarring	38
Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials	37
Plant-derived nanovesicles and therapeutic application	37
Prolactin and pain of endometriosis	37
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	37
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	37
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	37
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	37
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	36
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	36
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	35
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	35
Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities	34
Resolution of inflammation: An organizing principle in biology and medicine	34
The antidepressant actions of ketamine and its enantiomers	33
Biased signaling in drug discovery and precision medicine	33
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	33

Editorial Board	33
Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments	32
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	32
Editorial Board	32
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	31
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	31
Treatment of overdose in the synthetic opioid era	30
Gene and stem cell therapy for inherited cardiac arrhythmias	30
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	30
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	30
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	30
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	30
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	30
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	30
Anti-cancer activity of sustained release capsaicin formulations	30
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	30
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	30
Bile acids and neurological disease	30
Spotlight on plasticity-related genes: Current insights in health and disease	29
Artificial intelligence with mass spectrometry-based multimodal molecular profiling methods for advancing therapeutic discovery of infectious diseases	29
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy	29
Clinical advances in oncolytic virotherapy for pediatric brain tumors	29
Editorial Board	29
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?	29
Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression	29
Mechanistic insights into medulloblastoma relapse	29
Targeting immunoproteasome in neurodegeneration: A glance to the future	29
The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy	29
Microvascular basis of cognitive impairment in type 1 diabetes	29
Metabolomics, metabolic flux analysis and cancer pharmacology	28
Resolution of inflammation in oral diseases	28
Lessons learned from 20 years of preclinical testing in pediatric cancers	28
Oxytocin signaling in the treatment of drug addiction: Therapeutic opportunities and challenges	28
Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities	28
The cardiovascular effects of air pollution: Prevention and reversal by pharmacological agents	27
From exploring cancer and virus targets to discovering active peptides through mRNA display	27
A comprehensive review on pharmacokinetic mechanism of herb-herb/drug interactions in Chinese herbal formula	27
“RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)	27
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases	27
The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy	27
Targeting hedgehog signaling in pancreatic ductal adenocarcinoma	26
ThermoTRP channels in pain sexual dimorphism: new insights for drug intervention	26
Sex differences in eicosanoid formation and metabolism: A possible mediator of sex discrepancies in cardiovascular diseases	26
Exploring the “Other” subfamily of HECT E3-ligases for therapeutic intervention	26
Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders	26
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure	26
Antithrombotic therapy following transcatheter aortic valve intervention	26
Potential application of natural compounds in ischaemic stroke: Focusing on the mechanisms underlying “lysosomocentric” dysfunction of the autophagy-lysosomal pathway	26
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance	26
Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases	25
PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications	25
Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols	25
Advances in understanding cancer-associated neurogenesis and its implications on the neuroimmune axis in cancer	25
The future of targeted kinase inhibitors in melanoma	25
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis	25
Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies	25
Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications	25
The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine	24
The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges	24
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics	24
Editorial Board	24
A natural products solution to diabetic nephropathy therapy	24
Editorial Board	24
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?	24
Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions	24
The unique function of p130Cas in regulating the bone metabolism	23
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies	23
CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control	23
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways	23
Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma	23
The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans	22
TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies	22
Functional hydrogels as therapeutic tools for spinal cord injury: New perspectives on immunopharmacological interventions	22
Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan	22
Targeting selective autophagy in CNS disorders by small-molecule compounds	22
Overview of the role of purinergic signaling and insights into its role in cancer therapy	22
Editorial Board	22
Impact of drug treatment and drug interactions in post-stroke epilepsy	22
Emerging roles of lysophosphatidic acid receptor subtype 5 (LPAR5) in inflammatory diseases and cancer	22
Novel strategies exploiting interleukin-12 in cancer immunotherapy	22
Bioactive lipid regulation of platelet function, hemostasis, and thrombosis	22
Corrigendum to “Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges” [Pharmacology & Therapeut	22
Editorial Board	22
The role of the STAT3 signaling transduction pathways in radioresistance	22
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease	22
Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response	22
Targeting the dysfunction of glutamate receptors for the development of novel antidepressants	22
Role of inflammatory chemokines in hypertension	22
Understanding the physiological role of NaV1.9: Challenges and opportunities for pain modulation	22
Inflammation in kidney repair: Mechanism and therapeutic potential	22
Cytochrome P450-derived fatty acid epoxides and diols in angiogenesis and stem cell biology	21
The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?	21
Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells	21
The gabapentinoid drugs and their abuse potential	21
Potassium homeostasis – Physiology and pharmacology in a clinical context	21